AVANT to Present at the Roth Capital Partners 17th Annual Growth Stock Conference.DANA POINT, Calif. -- AVANT Immunotherapeutics, Inc. (Nasdaq:AVAN) today announced that Avery (Chip) W. Catlin, Senior Vice President and Chief Financial Officer of AVANT Immunotherapeutics, Inc., will be presenting on Tuesday, February 22nd, at 3:00 p.m. PST PST Paroxysmal supraventricular tachycardia, see there at the Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, 17th Annual Growth Stock Conference taking place at the St. Regis Monarch Beach Resort and Spa in Dana Point, CA. A live webcast of the presentation, together with a read-only copy of the presentation slides in Adobe Acrobat Document exchange software from Adobe that allows documents to be displayed and printed the same on every computer. The Acrobat system created the Portable Document Format (PDF), which is widely used in commercial printing and on the Web. See PDF. (.pdf) format, will be available online via the Investor Information area of AVANT's website at http://www.avantimmune.com and at http://www.wsw.com/webcast/roth5/avan. An archive of the webcast will be available via AVANT's website for 90 days following the event. A conference agenda is posted on Roth Capital's web site at www.rothcp.com. About AVANT AVANT Immunotherapeutics, Inc. discovers, develops and sells innovative vaccines and therapeutics that harness the human immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to prevent and treat disease. The company has developed a broad, well-staged pipeline of vaccines and therapeutics for large, high-value, under-served markets. Three of AVANT's products are marketed, including two food safety vaccines and an oral human rotavirus rotavirus /ro·ta·vi·rus/ (ro´tah-vi?rus) any member of the genus Rotavirus. ro´taviral Rotavirus /Ro·ta·vi·rus/ (ro´tah-vi?rus vaccine, which gained its first marketing approval in Mexico in July 2004. Six of AVANT's products are in clinical development, including a treatment to reduce complement-mediated tissue damage associated with cardiac bypass surgery Bypass surgery A surgical procedure that grafts blood vessels onto arteries to reroute the blood flow around blockages in the arteries (arteriosclerosis). and a novel vaccine for cholesterol management. AVANT has also assembled a technology platform that enables the creation of rapid-protecting, single-dose, oral vaccines that remain stable without refrigeration refrigeration, process for drawing heat from substances to lower their temperature, often for purposes of preservation. Refrigeration in its modern, portable form also depends on insulating materials that are thin yet effective. . The company is developing applications of this vaccine technology in four areas: biodefense, travelers' vaccines, global health needs, and human food safety. Further, AVANT has established a state-of-the-art vaccine manufacturing facility for the implementation of its VitriLife(R) technology and the production of its own vaccines and other companies' products. AVANT's goal is to demonstrate proof-of-concept for its products before leveraging further development through both traditional pharmaceutical partnerships and collaborations with governmental and other organizations. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com. About the Roth Capital Partners 17th Annual Growth Stock Conference This conference will feature more than 220 leading growth companies in sectors such as Technology, Healthcare, Financial Services The examples and perspective in this article or section may not represent a worldwide view of the subject. Please [ improve this article] or discuss the issue on the talk page. and Consumer Products. A concentrated, two-day program will allow institutional investors to meet the executives from a select group of companies that have been hand picked by the Roth Capital Partners research team. 40% of this year's participating companies are presenting here for the first time. The average market cap of this year's presenters is around $330 million, with the median around $185 million. This closely mirrors the average and median market cap Median market cap The midpoint of market capitalization (market price multiplied by the number of shares outstanding) of the stocks in a portfolio. Half the stocks in the portfolio will have higher market capitalizations; half will have lower. for the proposed Russell Microcap microcap 1. Of or relating to the common stock of a company with a small capitalization, usually between $50 million and $250 million. Microcap stocks tend to experience volatile price movements and are subject to investment fraud schemes. (TM)Index which is expected to be around $277 million and $176 million respectively. To register for this conference, please contact your Roth sales representative at 800-678-9147. Please note that this conference is by invitation only. For more information about the conference visit: http://www.rothcp.com/2005%20DP%20Conference%20Web%20Site/Roth%20DP. html?content=home |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion